Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
NCT04833465
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect initial pilot data in three distinct patient groups.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Juvenile Idiopathic Arthritis
- Systemic Lupus Erythematosus
- Fibromyalgia
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 5 to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Children's National Research Institute
- Last updated on ClinicalTrials.gov
- July 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Children's National Health System · Washington D.C., DC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.